Document Detail


Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators.
MedLine Citation:
PMID:  2061979     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To determine whether clinical selection for thrombolytic therapy for acute myocardial infarction results in a skewed population for subsequent adverse cardiovascular events. DESIGN: A comparison of the clinical features of the patients in the Survival and Ventricular Enlargement Study who either had or had not received thrombolytic therapy was conducted in both univariate and multiple logistic regression analyses. SETTING: Hospitalized patients experiencing acute myocardial infarction from 112 broadly representative, private, academic, and government hospitals in the United States and Canada. PATIENTS: All patients in the Survival and Ventricular Enlargement Study had had a recent myocardial infarction (less than 16 days) and had a left ventricular ejection fraction of 40% or less. INTERVENTION: Thrombolytic therapy was administered to 733 patients and was not given to 1498. MAIN OUTCOME MEASURES: The comparisons with respect to use of thrombolytic therapy were formulated after the completion of enrollment and indicated that the majority of patients did not receive thrombolytic therapy. RESULTS: The 1498 (67.1%) patients who did not receive thrombolytic therapy were at higher risk (older age, lower functional capacity, greater likelihood of a history of prior myocardial infarction, angina, diabetes, and hypertension) for subsequent cardiovascular events and, as anticipated, were more likely to have concomitant gastrointestinal and neurological diseases. A multiple logistic regression analysis indicated that older age, prior myocardial infarction, impaired functional status, employment status, diabetes, and neurological diseases were predictors of use of thrombolytic therapy. CONCLUSION: Although the Survival and Ventricular Enlargement Study population was selected for left ventricular dysfunction, the majority of patients who currently are judged clinically as unsuitable for thrombolytic therapy have a higher risk for adverse cardiovascular events.
Authors:
M A Pfeffer; L A Moy?; E Braunwald; L Basta; E J Brown; T E Cuddy; G R Dagenais; G O Flaker; E M Geltman; B J Gersh
Related Documents :
3592299 - Myocardial reperfusion by thrombolysis after acute total left main artery occlusion--a ...
12182909 - Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute my...
1430679 - Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarctio...
2496939 - Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarct...
8445189 - Thrombolytic therapy in review.
8170179 - Coronary angioplasty in acute myocardial infarction: primary, immediate adjunctive, res...
3401109 - An introduction to high-resolution ecg recordings of cardiac late potentials.
20876969 - Numerically simulated cardiac exposure to electric current densities induced by taser x...
8780329 - Evolving role of sotalol in the management of ventricular tachyarrhythmias.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  JAMA : the journal of the American Medical Association     Volume:  266     ISSN:  0098-7484     ISO Abbreviation:  JAMA     Publication Date:    1991 Jul 24-31
Date Detail:
Created Date:  1991-08-06     Completed Date:  1991-08-06     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  528-32     Citation Subset:  AIM; IM    
Affiliation:
Harvard Medical School, Brigham and Women's Hospital, Boston, Mass 02115.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Captopril / therapeutic use*
Female
Humans
Male
Middle Aged
Myocardial Infarction / drug therapy*,  mortality,  physiopathology
Recurrence
Regression Analysis
Selection Bias
Stroke Volume
Thrombolytic Therapy*
Chemical
Reg. No./Substance:
62571-86-2/Captopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A prospective study of aspirin use and primary prevention of cardiovascular disease in women.
Next Document:  Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiologic...